Cargando…

Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation

INTRODUCTION: Until recently, patients discontinuing first-line (1L) hedgehog inhibitors (HHIs) for basal cell carcinoma (BCC) had few subsequent treatment options. The objective of this study was to describe the treatment journey and prognosis of patients discontinuing 1L HHI for BCC. METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cowey, Lance, Chen, Chieh-I., Aguilar, Kathleen M., Davies, Kalatu, LaFontaine, Patrick R., Fury, Matthew G., Bowler, Timothy, Golozar, Asieh, Jalbert, Jessica J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110576/ https://www.ncbi.nlm.nih.gov/pubmed/35507216 http://dx.doi.org/10.1007/s13555-022-00724-y

Ejemplares similares

Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy
por: Cowey, C. Lance, et al.
Publicado: (2020)

Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
por: Cowey, C. Lance
Publicado: (2013)

Qualitative Patient Interviews to Characterize the Human Burden of Advanced Basal Cell Carcinoma Following Hedgehog Pathway Inhibitor Treatment
por: Konidaris, Gerasimos, et al.
Publicado: (2023)

Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: A retrospective, community oncology-based cohort study (A STROBE-compliant article)
por: Cowey, C. Lance, et al.
Publicado: (2019)

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
por: Shire, Norah J., et al.
Publicado: (2020)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
por: Uchida, Genta, et al.
Publicado: (2023)

Real‐World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR‐Merkel
por: Bhanegaonkar, Abhijeet, et al.
Publicado: (2021)

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2020)

Immunoprevention of Basal Cell Carcinomas with Recombinant Hedgehog-interacting Protein
por: Vogt, Annika, et al.
Publicado: (2004)

Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis
por: Cowey, Charles Lance, et al.
Publicado: (2021)

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
por: Cowey, C Lance
Publicado: (2013)

Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma
por: Jalbert, Jessica J., et al.
Publicado: (2022)

Reasons for discontinuing insulin and factors associated with insulin discontinuation in patients with type 2 diabetes mellitus: a real-world evidence study
por: Wu, Jianmin, et al.
Publicado: (2021)

Tolerability and discontinuation rates in teriflunomide-treated patients: A real-world clinical experience
por: Alnajashi, Hind A., et al.
Publicado: (2018)

Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
por: Chan, Andrew, et al.
Publicado: (2020)

Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis
por: Fujita, Ryo, et al.
Publicado: (2022)

Hedgehog signaling pathway and its targets for treatment in basal cell carcinoma
por: Cucchi, Danilo, et al.
Publicado: (2012)

Hedgehog signaling promotes basal progenitor expansion and the growth and folding of the neocortex
por: Wang, Lei, et al.
Publicado: (2016)

Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response
por: Gambini, Donatella, et al.
Publicado: (2022)

Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial
por: Ortega, Hector, et al.
Publicado: (2019)

Clopidogrel Therapy Discontinuation Following Drug Eluting Stent Implantation in Real World Practice in Israel
por: Blich, Miry, et al.
Publicado: (2012)

Real-world Discontinuation of Antidepressant Treatment in Patients with Burning Mouth Syndrome: A Chart Review
por: Watanabe, Motoko, et al.
Publicado: (2019)

Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real‐World Study Across Antipsychotics
por: Stam, Noraly, et al.
Publicado: (2020)

Predictors for self-discontinuation of anti-osteoporosis medication: A hospital-based real-world study
por: Deng, Ya-Lian, et al.
Publicado: (2022)

Motives, frequency, predictors and outcomes of MRA discontinuation in a real-world heart failure population
por: Jonsson Holmdahl, Anna, et al.
Publicado: (2022)

The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma
por: John, Lijo, et al.
Publicado: (2015)

Evaluation of the ‘Hedgehog’ signaling pathways in squamous and basal cell carcinomas of the eyelids and conjunctiva
por: CELEBI, ALI RIZA CENK, et al.
Publicado: (2016)

Expression profile of sonic hedgehog signaling-related molecules in basal cell carcinoma
por: Kim, Hye Sung, et al.
Publicado: (2019)

Hedgehog Pathway Inhibitors: Clinical Implications and Resistance in the Treatment of Basal Cell Carcinoma
por: Habashy, Suzanne, et al.
Publicado: (2021)

Activation of the Hedgehog and Wnt/β-Catenin Signaling Pathways in Basal Cell Carcinoma
por: Takada, Tomoaki
Publicado: (2021)

Modulation of Hedgehog Signaling for the Treatment of Basal Cell Carcinoma and the Development of Preclinical Models
por: Dukes, Meghan W., et al.
Publicado: (2022)

Expression of Hedgehog Signaling Pathway Proteins in Basal Cell Carcinoma: Clinicopathologic Study
por: Deng, Li-Jia, et al.
Publicado: (2022)

Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma
por: VERKOUTEREN, Babette J. A., et al.
Publicado: (2022)

Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States
por: Puenpatom, Amy, et al.
Publicado: (2017)

Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution
por: Cerveira, Nuno, et al.
Publicado: (2018)

Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia
por: Evdoshenko, Evgeniy, et al.
Publicado: (2019)

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma
por: Pokorny, Rebecca, et al.
Publicado: (2021)

Early discontinuation of biological therapy among inflammatory bowel disease patients in Bahrain: Real world experience
por: Abdulla, Maheeba, et al.
Publicado: (2022)

P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION
por: Passamonti, F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_khi62cms9a2175k3cdiqlpbkrh